Vilanterol
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Vilanterol and local guidelines before prescribing.
Long-acting beta-2 agonist
Mechanism
Ultra-long-acting beta-2 agonist (in combination inhalers).
Uses
Asthma and COPD (with inhaled steroid or antimuscarinic).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Tremor, palpitations, headache, cough.
Interactions
Beta-blockers; ketoconazole.
Contraindications and cautions
Not for acute relief
Monitoring
Asthma control
Pregnancy and breastfeeding
Acceptable
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Once-daily combination inhalers.
More from the textbook: uses, cautions and other points
- LABA + LAMA (e.g. umeclidinium–vilanterol, tiotropium–olodaterol) - first-line regular treatment for most people with COPD who remain breathless (NICE NG115).
Respiratory: Anatomy, Physiology and Pharmacology - LABA (long-acting) - salmeterol (slow onset, 12 hours), formoterol ( fast onset , 12 hours - allows use as a reliever in MART/AIR), vilanterol, olodaterol, indacaterol (24 hours).
Respiratory: Anatomy, Physiology and Pharmacology - ICS + LABA - budesonide–formoterol, beclometasone–formoterol, fluticasone–salmeterol, fluticasone furoate–vilanterol.
Respiratory: Anatomy, Physiology and Pharmacology - Triple therapy (LABA + LAMA + ICS in one inhaler - e.g. fluticasone furoate–umeclidinium–vilanterol, beclometasone–formoterol–glycopyrronium) - COPD with continued exacerbations (especially with raised eosinophils or asthmatic features); severe asthma.
Respiratory: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (4 mentions)